查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全基因及EXOME序列市場:各用途，生物，各產品，全基因及EXOME - 附執行顧問指南，D2C分析與人工智能的影響(2025年～2029年)
市場調查報告書
商品編碼
1720944

全基因及EXOME序列市場:各用途，生物，各產品，全基因及EXOME - 附執行顧問指南，D2C分析與人工智能的影響(2025年～2029年)

Whole Genome and Exome Sequencing Markets. By Application, Organism, Product and Whole/Exome with Executive and Consultant Guides. Includes Direct to Consumer Analysis and Impact of Artificial Intelligence. 2025 to 2029
出版日期: | 出版商: Howe Sound Research | 英文 681 Pages | 商品交期: 最快1-2個工作天內

價格

每個新生兒出生時都會接受全基因體定序嗎？直接面向消費者的檢測將成長多快？哪種定序技術將佔據主導地位？了解阻礙產業發展的因素，以及超過 800 家部署高通量儀器的實驗室的概述等。

新消費者、新科技、新專業。在令人聯想到網路產業誕生的環境下，各種資金雄厚的參與者正在真正的全球舞台上爭奪市場佔有率。本報告預測了五年後的市場規模，並詳細分析了 14 個國家和 5 個地區。

我們用簡單易懂的術語來解釋這項技術：腫瘤細胞定序、直接面向消費者、基因表現等等。它還總結了未來五年的成長預測和最終市場預測，包括挑戰、機會和陷阱。

所有報表資料可依需求提供Excel格式。您可以根據最新數據自信地做出投資決策和估值。

本報告提供全球全基因及EXOME序列市場相關調查，市場概要，以及各用途，生物，各產品，按全基因及EXOME趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場指南

第2章 簡介和市場定義

  • 本報告中全基因組定序的定義
  • 基因體學革命
  • 市場定義
  • 研究方法
  • 視角：醫療保健和體外診斷 (IVD) 行業
  • 基因組的大小－並非您所想
  • 全球高通量定序設施清單—位置與聯絡方式

第3章 市場概要

  • 完成各種各樣的作用的市場進入組織
    • 設備廠商
    • 專門的獨立型研究室
    • 國內/地區的獨立型研究所
    • 獨立型臨床檢驗室
    • 公共的國立/地區研究所
    • 醫院檢驗室
    • 臨床檢驗室
    • DTC實驗室
    • 定序實驗室
    • 審核機關
  • 全基因定序- 市場，案例，考察
  • 產業結構

第4章 市場趨勢

  • 成長促進因素
  • 阻礙成長的要素
  • 定序設備

第5章 全基因及EXOME序列的最近的趨勢

第6章 主要企業的簡介

  • 10x Genomics, Inc.
  • 1928 Diagnostics
  • 23andME Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agilent/Dako
  • Akonni Biosystems
  • Amoy Diagnostics Co., Ltd.
  • Ancestry.com LLC
  • Anchor Dx
  • ARUP Laboratories
  • BaseClear
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • C2i Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • CosmosID
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics.
  • Diasorin S.p.A.
  • Element Biosciences
  • Element Biosciences
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Fabric Genomics
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fulgent Genetics
  • GE Global Research
  • Gencove
  • Genedrive
  • GeneDx Holdings
  • GeneFirst Ltd.
  • Genetron Holdings
  • Genewiz
  • Genomics England
  • Genomics Personalized Health(GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helix OpCo
  • Helomics
  • Hologic
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Lunglife AI Inc
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech(Thermo Fisher)
  • Mesa Laboratories, Inc.
  • miR Scientific
  • MNG Labs
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New England Biolabs, Inc.
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • Oncocyte
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Pathogenomix
  • PathoQuest S.A.
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • QuantuMDx
  • Regeneron Pharmaceuticals
  • Revvity
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • SkylineDx
  • Standard BioTools
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Ultima Genomics
  • Ultima Genomics
  • Variantyx
  • Volition
  • Vyant Bio
  • Zymo Research Corp

第7章 全球全基因定序市場

  • 各國全球市場概要
  • 各用途全球市場- 概要
  • 生物全球市場- 概要
  • 各產品全球市場- 概要
  • 全基因/EXOME全球市場- 概要

第8章 全球全基因測序市場- 各用途

  • 研究
  • 人臨床
  • 人臨床 - 迅速
  • 臨床 - 腫瘤
  • 臨床 - 病原體
  • D2C
  • 農業/其他

第9章 全球全基因定序市場- 生物

  • 人
  • 病原體
  • 其他

第10章 全球全基因定序市場- 各產品

  • 設備
  • 試劑
  • 分析
  • 軟體和其他

第11章 全球全基因測序市場- 全基因/EXOME

  • 全基因
  • 只EXOME
  • 其他/混合

第12章 全基因定序的未來願景

第13章 附錄

OVERVIEW:

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are over 800 locations that have high throughput devices?

Our facts and support = Your success.

New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out five years. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

  • 1.1. Whole Genome Sequencing Market - Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors
  • 1.4. Impact of Artificial Intelligence on WGS

2. Introduction and Market Definition

  • 2.1. Whole Genome Sequencing Definition In This Report
    • 2.1.1. Whole and Exome Sequencing
    • 2.1.2. Research
    • 2.1.3. Clinical Human
    • 2.1.4. Clinical Human Rapid
    • 2.1.5. Clinical Tumor
    • 2.1.6. Clinical Pathogen
    • 2.1.7. Agri/Other
    • 2.1.8. Direct to Consumer
  • 2.2. The Genomics Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics
  • 2.6. Sizing the Genome - Not What You Think
    • 2.6.1. Cost, Price and Genome Size, Pricing Practice
  • 2.7. GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

3. Market Overview

  • 3.1. Market Participants Play Different Roles
    • 3.1.1. Instrument Manufacturer
    • 3.1.2. Independent lab specialized/esoteric
    • 3.1.3. Independent lab national/regional
    • 3.1.4. Independent lab analytical
    • 3.1.5. Public National/regional lab
    • 3.1.6. Hospital lab
    • 3.1.7. Physician lab
    • 3.1.8. DTC Lab
    • 3.1.9. Sequencing Labs
    • 3.1.10. Audit body
  • 3.2. Whole Genome Sequencing -Markets, Examples and Discussion
    • 3.2.1. Direct to Consumer - Two Approaches
      • 3.2.1.1. The New Age of Medical Information
      • 3.2.1.2. Dangers in DTC-WGS - Health Costs and Regulation
      • 3.2.1.3. Newborn and Prenatal - A Brave New World
      • 3.2.1.4. DTC - How Many Segments?
    • 3.2.2. Research Markets
      • 3.2.2.1. Research Funding and Capital Expense
      • 3.2.2.2. WGS Datasets Preferred
      • 3.2.2.3. Existing research repurposed
      • 3.2.2.4. Organism Wide Market
      • 3.2.2.5. Service Suppliers Respond
    • 3.2.3. Clinical - Understanding Germline and Somatic
      • 3.2.3.1. Somatic - Chasing Mutations and Pharmacogenomics
    • 3.2.4. Pathogen Testing
      • 3.2.4.1. The Hepatitis C Story
      • 3.2.4.2. Will theMicrobiology Department Disappear?
    • 3.2.5. AgriBio - Big Business
      • 3.2.5.1. GMO is Here to Stay
      • 3.2.5.2. WGS Benefits and Risks
      • 3.2.5.3. The New Agriculture
  • 3.3. Industry Structure
    • 3.3.1. Hospital's Testing Share
    • 3.3.2. Economies of Scale
    • 3.3.3. Instrument Manufacturer Role
    • 3.3.4. Healthcare Industry Impacts - Still Struggling
      • 3.3.4.1. Can the Healthcare Industry Adapt?
      • 3.3.4.2. Genetic Counselling as an Industry
      • 3.3.4.3. WGES Adoption and Cannibalization
      • 3.3.4.4. The Meaning of Grail

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Diagnostic Factors
    • 4.1.2. Interpreting the Code Otherwise
    • 4.1.3. Changes in Agriculture
    • 4.1.4. Fertility Technology Comes of Age
    • 4.1.5. Pathogen Challenges
  • 4.2. Factors Limiting Growth
    • 4.2.1. Increased Competition Lowers Price
    • 4.2.2. Lower Costs
    • 4.2.3. Healthcare Cost Concerns Curtail Growth
    • 4.2.4. Wellness has a downside
    • 4.2.5. GMO Opposition Movement
  • 4.3. Sequencing Instrumentation
    • 4.3.1. Instrumentation Tenacity
    • 4.3.2. Declining Cost Changes Industry Structure
    • 4.3.3. LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
    • 4.3.4. Illumina
    • 4.3.5. ION
    • 4.3.6. Pacific Biosystems
    • 4.3.7. Roche 454
    • 4.3.8. SOLiD
    • 4.3.9. Oxford Nanopore
      • 4.3.9.1. What is Oxford Nanopore Sequencing?
      • 4.3.9.2. What can Oxford Nanopore Sequencingt be used for?
      • 4.3.9.3. Oxford Nanopore Products
    • 4.3.10. Long Reads - Further Segmentation
    • 4.3.11. Linked Reads
    • 4.3.12. Targeted Sequencing Adopts CRISPR
    • 4.3.13. New Sequencing Technologies
      • 4.3.13.1. RNAP sequencing
      • 4.3.13.2. In vitro virus high-throughput sequencing
      • 4.3.13.3. Tunnelling currents DNA sequencing
      • 4.3.13.4. Sequencing by hybridization
      • 4.3.13.5. Sequencing with mass spectrometry
      • 4.3.13.6. Microfluidic Sanger sequencing
      • 4.3.13.7. Microscopy-based techniques

5. WGES Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. GeneDx to Acquire Fabric Genomics
  • 5.3. WGS provides faster detection of Salmonella
  • 5.4. UltraRapid WGS, Results in 48 Hours
  • 5.5. WGS Identifies Desirable Tobacco Genes
  • 5.6. The Case for WGS use in All Blood Cancers
  • 5.7. $400 Personal WGS
  • 5.8. Incorporating WGS into Cancer Care
  • 5.9. Epic, GeneDx to broaden WGS potential
  • 5.10. Qiagen QiaSeq xHyb Mycobacterium Tuberculosis Panel
  • 5.11. WGS Uncovers Genetic causes of cerebral palsy
  • 5.12. Rapid WGS Use recommended for Intensive Care
  • 5.13. Quest and Ultima Genomics to Develop Tests
  • 5.14. WHO launches WGS Guide
  • 5.15. Myriad Genetics to Study MRD Testing
  • 5.16. Adela Developing Epigenetic Multi-Cancer Detection
  • 5.17. Epic Sciences Expanding Infrastructure for Liquid Biopsy Test
  • 5.18. Bionano Laboratories Announces New Prenatal Whole Genome Tests
  • 5.19. Myriad Genetics Plans Product Launches
  • 5.20. Genomics England, Aims to Sequence 100K Newborns
  • 5.21. Juno Diagnostics NIPT With At-Home Sample Collection
  • 5.22. Cardio Diagnostics Launches Genetic Cardio Risk Test
  • 5.23. Universal Genetic Testing in Breast Cancer Further Supported
  • 5.24. Aniling Gets CE-IVD Marks for Cancer Sequencing Tests
  • 5.25. MyOme Lands Investment for WGS
  • 5.26. GenomSys Gains CE Mark for New Genomic Analysis Software
  • 5.27. WGS Finds Lung Cancers Fall Into Molecular Subtypes
  • 5.28. Testing Distinguishes Benign Tumors From Precancerous Condition
  • 5.29. Plan to Sequence All Newborns in UK
  • 5.30. Clear Labs Raises $60M for Nanopore Sequencing
  • 5.31. Variantyx Expands Into Prenatal, Cancer Testing
  • 5.32. Whole-Genome Sequencing Aids Diagnosis in Stockholm
  • 5.33. Variantyx Raises $20M
  • 5.34. Nonacus WGS Service for SARS-CoV-2 Laboratories
  • 5.35. Center to Report Risk Scores in Clinical WGS
  • 5.36. Stanford Launches WGS for Cardiovascular Testing
  • 5.37. Illumina and NY Healthcare Partner on Clinical WGS
  • 5.38. Increased Adoption of WGS Needs Acceptance by Payors, Providers
  • 5.39. Veritas Intercontinental Completes Euro-5M Series B Financing Round
  • 5.40. M2GEN and Discovery Life Sciences in Bioinformatics Agreement
  • 5.41. Genomics England Adopts Quantum ActiveScale Object Storage
  • 5.42. GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
  • 5.43. NHS Wales Introduces WGS for Critically Ill Newborns
  • 5.44. Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test
  • 5.45. C2i Genomics to Launch Trials for MRD Detection Tech
  • 5.46. Roche Acquires Sequencing Company Stratos Genomics
  • 5.47. UK COVID-19 Sequencing Consortium Launches
  • 5.48. Invitae Acquires Three Companies: YouScript, Genelex, Diploid
  • 5.49. Experience From Centralized Genomic Medicine Lab
  • 5.50. MGI to Enable $100 Human Genome
  • 5.51. Nebula Genomics offers $299 WGS
  • 5.52. Team to Study Campylobacter Omics
  • 5.53. Veritas Genetics Restarts US Business
  • 5.54. NEOGEN, Gencove partner to advance animal genomics

6. Profiles of Key Companies

  • 6.1. 10x Genomics, Inc.
  • 6.2. 1928 Diagnostics
  • 6.3. 23andME Inc.
  • 6.4. Abbott Laboratories
  • 6.5. AccuraGen Inc.
  • 6.6. Adaptive Biotechnologies
  • 6.7. Admera Health, LLC
  • 6.8. Agilent/Dako
  • 6.9. Akonni Biosystems
  • 6.10. Amoy Diagnostics Co., Ltd.
  • 6.11. Ancestry.com LLC
  • 6.12. Anchor Dx
  • 6.13. ARUP Laboratories
  • 6.14. BaseClear
  • 6.15. Baylor Miraca Genetics Laboratories
  • 6.16. Beckman Coulter Diagnostics
  • 6.17. Becton, Dickinson and Company
  • 6.18. BGI Genomics Co. Ltd
  • 6.19. Bioarray Genetics
  • 6.20. Biocept, Inc.
  • 6.21. Biodesix Inc.
  • 6.22. BioFluidica
  • 6.23. BioGenex
  • 6.24. Biolidics Ltd
  • 6.25. bioMerieux Diagnostics
  • 6.26. Bioneer Corporation
  • 6.27. Bio-Rad Laboratories, Inc
  • 6.28. Bio-Techne
  • 6.29. C2i Genomics
  • 6.30. Caris Molecular Diagnostics
  • 6.31. CellMax Life
  • 6.32. Centogene
  • 6.33. Circulogene
  • 6.34. Clear Labs
  • 6.35. Clinical Genomics
  • 6.36. Complete Genomics, Inc. - A BGI Company
  • 6.37. CosmosID
  • 6.38. Dante Labs
  • 6.39. Datar Cancer Genetics Limited
  • 6.40. Day Zero Diagnostics.
  • 6.41. Diasorin S.p.A.
  • 6.42. Element Biosciences
  • 6.43. Element Biosciences
  • 6.44. Epic Sciences
  • 6.45. Epigenomics AG
  • 6.46. Eurofins Scientific
  • 6.47. Excellerate Bioscience
  • 6.48. Fabric Genomics
  • 6.49. Freenome
  • 6.50. FUJIFILM Wako Diagnostics
  • 6.51. Fulgent Genetics
  • 6.52. GE Global Research
  • 6.53. Gencove
  • 6.54. Genedrive
  • 6.55. GeneDx Holdings
  • 6.56. GeneFirst Ltd.
  • 6.57. Genetron Holdings
  • 6.58. Genewiz
  • 6.59. Genomics England
  • 6.60. Genomics Personalized Health (GPH)
  • 6.61. GenomOncology
  • 6.62. Genzyme Corporation
  • 6.63. Grifols
  • 6.64. Guardant Health
  • 6.65. Guardiome
  • 6.66. HeiScreen
  • 6.67. Helix
  • 6.68. Helix OpCo
  • 6.69. Helomics
  • 6.70. Hologic
  • 6.71. HTG Molecular Diagnostics
  • 6.72. Human Longevity, Inc.
  • 6.73. iCellate
  • 6.74. Illumina
  • 6.75. Incell Dx
  • 6.76. Inivata
  • 6.77. Invitae Corporation
  • 6.78. Invivoscribe
  • 6.79. Karius
  • 6.80. Lunglife AI Inc
  • 6.81. Macrogen
  • 6.82. MDNA Life SCIENCES, Inc.
  • 6.83. MDx Health
  • 6.84. Medgenome
  • 6.85. Meridian Bioscience
  • 6.86. Mesa Biotech (Thermo Fisher)
  • 6.87. Mesa Laboratories, Inc.
  • 6.88. miR Scientific
  • 6.89. MNG Labs
  • 6.90. NantHealth, Inc.
  • 6.91. Natera
  • 6.92. Nebula Genomics
  • 6.93. NeoGenomics
  • 6.94. New England Biolabs, Inc.
  • 6.95. Novogene Bioinformatics Technology Co., Ltd.
  • 6.96. Omega Bioservices
  • 6.97. Oncocyte
  • 6.98. OncoDNA
  • 6.99. OpGen
  • 6.100. ORIG3N, Inc.
  • 6.101. Origene Technologies
  • 6.102. Oxford Nanopore Technologies
  • 6.103. Pacific Biosciences
  • 6.104. Panagene
  • 6.105. Pathogenomix
  • 6.106. PathoQuest S.A.
  • 6.107. Personal Genome Diagnostics
  • 6.108. Personalis
  • 6.109. Precipio
  • 6.110. PrecisionMed
  • 6.111. Promega
  • 6.112. Protagen Diagnostics
  • 6.113. Qiagen
  • 6.114. QuantuMDx
  • 6.115. Regeneron Pharmaceuticals
  • 6.116. Revvity
  • 6.117. Roche Molecular Diagnostics
  • 6.118. Roswell Biotechnologies
  • 6.119. Seegene
  • 6.120. Sequencing.com
  • 6.121. Siemens Healthineers
  • 6.122. simfo GmbH
  • 6.123. Singlera Genomics Inc.
  • 6.124. Singular Genomics
  • 6.125. SkylineDx
  • 6.126. Standard BioTools
  • 6.127. Sure Genomics, Inc.
  • 6.128. Sysmex
  • 6.129. Sysmex Inostics
  • 6.130. Tempus Labs, Inc.
  • 6.131. Thermo Fisher Scientific Inc.
  • 6.132. Ultima Genomics
  • 6.133. Ultima Genomics
  • 6.134. Variantyx
  • 6.135. Volition
  • 6.136. Vyant Bio
  • 6.137. Zymo Research Corp

7. The Global Market for Whole Genome Sequencing

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Application - Overview
    • 7.2.1. Table - Global Market by Application
    • 7.2.2. Chart - Global Market by Application - Base/Final Year Comparison
    • 7.2.3. Chart - Global Market by Application - Base Year
    • 7.2.4. Chart - Global Market by Application - Final Year
    • 7.2.5. Chart - Global Market by Application - Share by Year
    • 7.2.6. Chart - Global Market by Application - Segment Growth
  • 7.3. Global Market by Organism - Overview
    • 7.3.1. Table - Global Market by Organism
    • 7.3.2. Chart - Global Market by Organism - Base/Final Year Comparison
    • 7.3.3. Chart - Global Market by Organism - Base Year
    • 7.3.4. Chart - Global Market by Organism - Final Year
    • 7.3.5. Chart - Global Market by Organism - Share by Year
    • 7.3.6. Chart - Global Market by Organism - Segment Growth
  • 7.4. Global Market by Product - Overview
    • 7.4.1. Table - Global Market by Product
    • 7.4.2. Chart - Global Market by Product - Base/Final Year Comparison
    • 7.4.3. Chart - Global Market by Product - Base Year
    • 7.4.4. Chart - Global Market by Product - Final Year
    • 7.4.5. Chart - Global Market by Product - Share by Year
    • 7.4.6. Chart - Global Market by Product - Segment Growth
  • 7.5. Global Market by Whole/Exome - Overview
    • 7.5.1. Table - Global Market by Whole/Exome
    • 7.5.2. Chart - Global Market by Whole/Exome - Base/Final Year Comparison
    • 7.5.3. Chart - Global Market by Whole/Exome - Base Year
    • 7.5.4. Chart - Global Market by Whole/Exome - Final Year
    • 7.5.5. Chart - Global Market by Whole/Exome - Share by Year
    • 7.5.6. Chart - Global Market by Whole/Exome - Segment Growth

8. Global Whole Genome Sequencing Markets - by Application

  • 8.1. Research
    • 8.1.1. Table Research - by Country
    • 8.1.2. Chart - Research Growth
  • 8.2. Clinical Human
    • 8.2.1. Table Clinical Human - by Country
    • 8.2.2. Chart - Clinical Human Growth
  • 8.3. Clinical Human Rapid
    • 8.3.1. Table Clinical Human Rapid - by Country
    • 8.3.2. Chart - Clinical Human Rapid Growth
  • 8.4. Clinical Tumor
    • 8.4.1. Table Clinical Tumor - by Country
    • 8.4.2. Chart - Clinical Tumor Growth
  • 8.5. Clinical Pathogen
    • 8.5.1. Table Clinical Pathogen - by Country
    • 8.5.2. Chart - Clinical Pathogen Growth
  • 8.6. Direct to Consumer
    • 8.6.1. Table Direct to Consumer - by Country
    • 8.6.2. Chart - Direct to Consumer Growth
  • 8.7. Agriculture/Other
    • 8.7.1. Table Agriculture/Other - by Country
    • 8.7.2. Chart - Agriculture/Other Growth

9. Global Whole Genome Sequencing Markets - by Organism

  • 9.1. Human
    • 9.1.1. Table Human - by Country
    • 9.1.2. Chart - Human Growth
  • 9.2. Pathogen
    • 9.2.1. Table Pathogen - by Country
    • 9.2.2. Chart - Pathogen Growth
  • 9.3. Other Organism
    • 9.3.1. Table Other Organism - by Country
    • 9.3.2. Chart - Other Organism Growth

10. Global Whole Genome Sequencing Markets - by Product

  • 10.1. Instruments
    • 10.1.1. Table Instruments - by Country
    • 10.1.2. Chart - Instruments Growth
  • 10.2. Reagents
    • 10.2.1. Table Reagents - by Country
    • 10.2.2. Chart - Reagent Growth
  • 10.3. Analysis
    • 10.3.1. Table Analysis - by Country
    • 10.3.2. Chart - Analysis Growth
  • 10.4. Software & Other
    • 10.4.1. Table Software & Other - by Country
    • 10.4.2. Chart - Software & Other Growth

11. Global Whole Genome Sequencing Markets - by Whole/Exome

  • 11.1. Whole Genome
    • 11.1.1. Table Whole Genome - by Country
    • 11.1.2. Chart - Whole Genome Growth
  • 11.2. Exome Only
    • 11.2.1. Table Exome Only - by Country
    • 11.2.2. Chart - Exome Only Growth
  • 11.3. Other/Mix
    • 11.3.1. Table Other/Mix - by Country
    • 11.3.2. Chart - Other/Mix Growth

12. Vision of the Future of Whole Genome Sequencing

13. Appendices

  • 13.1. United States Medicare System: Laboratory Fees Schedule
  • 13.2. The Most Used IVD Assays
  • 13.3. The Highest Grossing Assays
  • 13.4. The Whole Genome Sequence of SARS-CoV-2

Table of Tables

  • Table 1: The Base Pairs
  • Table 2: Most Common Traditional Genetic Disorders
  • Table 3: List of GLOBAL SEQUENCING LOCATIONS
  • Table 4: Market Players by Type
  • Table 5: The Different Markets for Whole Genome Sequencing
  • Table 6: DTC Sub Segments
  • Table 7: Roles of WGS in AgriBio
  • Table 8: The Factors Driving Growth
  • Table 9: Factors Limiting Growth
  • Table 10: Listing of Current NGS Instrument Specifications
  • Table 11: Six New Sequencing Technologies
  • Table 12: Global Market by Region
  • Table 13: Global Market by Application
  • Table 14: Global Market by Organism
  • Table 15: Global Market by Product
  • Table 16: Global Market by Whole/Exome
  • Table 17: Research by Country
  • Table 18: Clinical Human by Country
  • Table 19: Clinical Human Rapid by Country
  • Table 20: Clinical Tumor by Country
  • Table 21: Clinical Pathogen by Country
  • Table 22: Direct to Consumer by Country
  • Table 23: Agriculture/Other by Country
  • Table 24: Human by Country
  • Table 25: Pathogen by Country
  • Table 26: Other Organism by Country
  • Table 27: Instruments by Country
  • Table 28: Reagents by Country
  • Table 29: Analysis by Country
  • Table 30: Software & Other by Country
  • Table 31: Whole Genome by Country
  • Table 32: Exome Only by Country
  • Table 33: Other/Mix by Country
  • Table 34: Clinical Lab Fee Schedule
  • Table 35: The Most Common Assays
  • Table 36: Largest Revenue Assays

Table of Figures

  • Figure 1: Global Healthcare Spending
  • Figure 2: The Lab Test Pie
  • Figure 3: Size of Genome for Various Species
  • Figure 4: Cost To Sequence a Human Genome
  • Figure 5: Base Year Country Market Share Chart
  • Figure 6: Global Market by Application - Base vs. Final Year
  • Figure 7: Global Market by Application Base Year
  • Figure 8: Global Market by Application Final Year
  • Figure 9: Application Type Share by Year
  • Figure 10: by Application Segment Growth
  • Figure 11: by Organism - Base vs. Final Year
  • Figure 12: by Organism Market Base Year
  • Figure 13: by Organism Market Final Year
  • Figure 14: by Organism Share by Year
  • Figure 15: by Organism Segment Growth
  • Figure 16: by Product - Base vs. Final Year
  • Figure 17: by Product Market Base Year
  • Figure 18: by Product Market Final Year
  • Figure 19: by Product Share by Year
  • Figure 20: by Product Segment Growth
  • Figure 21: by Whole/Exome - Base vs. Final Year
  • Figure 22: by Whole/Exome Market Base Year
  • Figure 23: by Whole/Exome Market Final Year
  • Figure 24: by Whole/Exome Share by Year
  • Figure 25: by Whole/Exome Segment Growth
  • Figure 26: Research Growth
  • Figure 27: Clinical Human Growth
  • Figure 28: Clinical Human Growth
  • Figure 29: Clinical Tumor Growth
  • Figure 30: Clinical Pathogen Growth
  • Figure 31: Direct to Consumer Growth
  • Figure 32: Agriculture/Other Growth
  • Figure 33: Human Growth
  • Figure 34: Pathogen Growth
  • Figure 35: Other Organism Growth
  • Figure 36: Instruments Growth
  • Figure 37: Reagent Growth
  • Figure 38: Analysis Growth
  • Figure 39: Software & Other Growth
  • Figure 40: Whole Genome Growth
  • Figure 41: Exome Only Growth
  • Figure 42: Other/Mix Growth